CN107206097A - 用于治疗急性、术后或慢性疼痛的组合物及其使用方法 - Google Patents

用于治疗急性、术后或慢性疼痛的组合物及其使用方法 Download PDF

Info

Publication number
CN107206097A
CN107206097A CN201580062137.2A CN201580062137A CN107206097A CN 107206097 A CN107206097 A CN 107206097A CN 201580062137 A CN201580062137 A CN 201580062137A CN 107206097 A CN107206097 A CN 107206097A
Authority
CN
China
Prior art keywords
anticonvulsant
biodegradable carrier
composition
days
end value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580062137.2A
Other languages
English (en)
Chinese (zh)
Inventor
弗朗西斯·M·雷诺兹
詹森·M·克里肖内
尼古拉斯·B·沃思
戴海宁
罗伯特·S·兰格
帕特里克·A·阿姆斯特朗
陈熙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mr Peake's Co
Original Assignee
Mr Peake's Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mr Peake's Co filed Critical Mr Peake's Co
Publication of CN107206097A publication Critical patent/CN107206097A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580062137.2A 2014-11-18 2015-02-23 用于治疗急性、术后或慢性疼痛的组合物及其使用方法 Pending CN107206097A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081162P 2014-11-18 2014-11-18
US62/081,162 2014-11-18
PCT/US2015/017112 WO2016081022A1 (en) 2014-11-18 2015-02-23 Compositions for treating acute, post-operative, or chronic pain and methods of using the same

Publications (1)

Publication Number Publication Date
CN107206097A true CN107206097A (zh) 2017-09-26

Family

ID=55960737

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580062137.2A Pending CN107206097A (zh) 2014-11-18 2015-02-23 用于治疗急性、术后或慢性疼痛的组合物及其使用方法
CN201580062194.0A Pending CN107405351A (zh) 2014-11-18 2015-11-11 用于治疗急性、术后或慢性疼痛的组合物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580062194.0A Pending CN107405351A (zh) 2014-11-18 2015-11-11 用于治疗急性、术后或慢性疼痛的组合物及其使用方法

Country Status (10)

Country Link
US (3) US20160136179A1 (enExample)
EP (2) EP3220955A4 (enExample)
JP (2) JP2017537881A (enExample)
CN (2) CN107206097A (enExample)
AU (2) AU2015350554A1 (enExample)
BR (2) BR112017010430A2 (enExample)
CA (2) CA2967287A1 (enExample)
IL (2) IL251881A0 (enExample)
MX (2) MX2017006388A (enExample)
WO (3) WO2016081022A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147147A1 (en) * 2016-02-23 2017-08-31 PixarBio Corporation Compositions comprising nav1.7 selective inhibitors for treating acute, post-operative, or chronic pain and methods of using the same
CN106902095B (zh) * 2017-03-08 2021-11-05 东北林业大学 一种集化疗与免疫疗法为一体的载黄芩苷纳米制剂及其制备方法
US11571429B2 (en) * 2017-05-23 2023-02-07 Upexmed Co. Ltd. Method and compounds for treating peripheral neuropathy
US20180338929A1 (en) * 2017-05-23 2018-11-29 Soon Kap Hahn Method and Compounds for Treating Peripheral Neuropathy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102348468B (zh) * 2009-07-31 2014-11-05 西安力邦医药科技有限责任公司 微球药物载体、其制备方法、组合物及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
IL86211A (en) * 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
US5948384A (en) * 1990-09-14 1999-09-07 Syngenix Limited Particulate agents
US20030056896A1 (en) * 1995-05-12 2003-03-27 Frank Jao Effective therapy for epilepsies
MX9700850A (es) * 1995-06-09 1997-09-30 Euro Celtique Sa Formulaciones y metodos para proporcionar anestesia local prolongada.
AU2003298749A1 (en) * 2002-11-26 2004-06-18 Seacoast Neuroscience, Inc. Buoyant polymer particles delivering therapeutic agents
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
AU2005314133B2 (en) * 2004-12-06 2012-03-08 Medicinova, Inc. Ibudilast for treating neuropathic pain and associated syndromes
US20100204178A1 (en) * 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US20080069857A1 (en) * 2006-04-12 2008-03-20 Yoon Yeo Compositions And Methods For Inhibiting Adhesions
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
EP2019691B1 (en) * 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymers for functional particles
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
GB0625322D0 (en) * 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
WO2009109911A1 (en) * 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
JP5841708B2 (ja) * 2008-07-01 2016-01-13 日東電工株式会社 表面被覆微粒子の医薬組成物
EP2460539A4 (en) * 2009-07-31 2013-12-04 Xi An Libang Medical Technology Co Ltd MEDICAMENT IN THE FORM OF NANO OR MICROBALLS, METHOD FOR THE PRODUCTION THEREOF AND COMPOSITION THEREOF AND USE THEREOF
WO2012031205A2 (en) * 2010-09-03 2012-03-08 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
US9301946B2 (en) * 2010-12-03 2016-04-05 Warsaw Orthopedic, Inc. Clonidine and GABA compounds in a biodegradable polymer carrier
PL3415139T3 (pl) * 2011-06-14 2022-07-11 Neurelis, Inc. Podawanie benzodiazepiny
RU2014112958A (ru) * 2011-09-21 2015-10-27 Йиссум Ресерч Девелопмент Компани оф де Хебрю Юниверсити оф Джерусалем Лтд. Наносистемы доставки для мирнк
EP2925327B1 (en) * 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
CN103610664B (zh) * 2013-12-11 2015-09-16 中国药科大学 一种制备卡马西平聚乳酸-羟基乙酸共聚物微胶囊的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102348468B (zh) * 2009-07-31 2014-11-05 西安力邦医药科技有限责任公司 微球药物载体、其制备方法、组合物及应用

Also Published As

Publication number Publication date
JP2017533943A (ja) 2017-11-16
MX2017006388A (es) 2017-08-21
US20170224621A1 (en) 2017-08-10
BR112017010428A2 (pt) 2017-12-26
AU2015350554A1 (en) 2017-04-27
IL251881A0 (en) 2017-06-29
CA2967287A1 (en) 2016-05-26
BR112017010430A2 (pt) 2017-12-26
MX2017006422A (es) 2017-09-12
CA2967335A1 (en) 2016-05-26
IL251880A0 (en) 2017-06-29
US20160317446A1 (en) 2016-11-03
WO2016081236A1 (en) 2016-05-26
EP3220955A4 (en) 2018-07-25
EP3220955A1 (en) 2017-09-27
AU2015350347A1 (en) 2017-05-04
EP3220917A4 (en) 2018-07-25
CN107405351A (zh) 2017-11-28
US20160136179A1 (en) 2016-05-19
JP2017537881A (ja) 2017-12-21
WO2016081022A1 (en) 2016-05-26
EP3220917A1 (en) 2017-09-27
WO2016081445A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
Huang et al. Intra-articular drug delivery systems for osteoarthritis therapy: Shifting from sustained release to enhancing penetration into cartilage
Erdoğar et al. Nanocapsules for drug delivery: an updated review of the last decade
JP6570513B2 (ja) 持続的眼内放出のためのマイクロスフェア薬剤送達システム
US20160136094A1 (en) Compositions For Treating Acute, Post-Operative, or Chronic Pain and Methods of Using the Same
US20180256502A1 (en) Compositions Comprising NAv1.7 Selective Inhibitors For Treating Acute, Post-Operative, Or Chronic Pain And Methods Of Using The Same
ES2770273T3 (es) Administración inyectable de micropartículas y composiciones para ello
JP2008502690A (ja) リン脂質組成物ならびにその調製方法および使用方法
KR20100127267A (ko) 저점도이면서 고도 응집된 유리체내 주사용 트리암시놀론 아세토니드 현탁액
US20210186988A1 (en) Pharmaceutical compositions and uses thereof
JPWO1999012571A1 (ja) 関節内疾患治療用のナノカプセル製剤
CN107206097A (zh) 用于治疗急性、术后或慢性疼痛的组合物及其使用方法
Mfoafo et al. Improved inner ear drug delivery using hydrogel carriers
Xiong et al. A silk-based hydrogel containing dexamethasone and lipoic acid microcrystals for local delivery to the inner ear
US20250114320A1 (en) Microspheres for extended release of fenofibrate
US20160136095A1 (en) Methods for treating epilepsy or seizure disorders
Marques et al. PKPD of PLGA-PEG-PLGA Copolymeric Micelles
KR101764004B1 (ko) 골관절염 예방 또는 치료용, 또는 관절 통증 완화용 주사제 조성물
JP7731501B2 (ja) 水性ゲル組成物
WO2017200700A1 (en) Methods for treating incisional pain
JP7518627B2 (ja) 薬剤徐放性組成物
Baldha et al. Biodegradable Polymers and Long-Acting Parenteral Formulations: An Overview

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170926

WD01 Invention patent application deemed withdrawn after publication